Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. - Wikidata - wikimedia - TriplyDB

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

http://www.wikidata.org/entity/Q35133371

about

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade A chaperone trap contributes to the onset of cystic fibrosis.Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes Transthyretin deposition in articular cartilage: a novel mechanism in the pathogenesis of osteoarthritis.Mutasynthesis of a potent anticancer sibiromycin analogue Transthyretin (TTR) cardiac amyloidosis.Natural biomolecules and protein aggregation: emerging strategies against amyloidogenesis Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.Age-related oxidative modifications of transthyretin modulate its amyloidogenicity Resveratrol administration increases Transthyretin protein levels ameliorating AD features - importance of transthyretin tetrameric stability.The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.The transthyretin amyloidoses: advances in therapy.Improving strategies for the diagnosis of cardiac amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.Mechanistic Contributions of Biological Cofactors in Islet Amyloid Polypeptide Amyloidogenesis.Viewing Extrinsic Proteotoxic Stress Through the Lens of Amyloid Cardiomyopathy.Mechanistic basis for the recognition of a misfolded protein by the molecular chaperone Hsp90.Modulation of amyloid assembly by glycosaminoglycans: from mechanism to biological significance.New insights into the roles of sulfated glycosaminoglycans in islet amyloid polypeptide amyloidogenesis and cytotoxicity.Cancer Chemoprevention by Resveratrol: The p53 Tumor Suppressor Protein as a Promising Molecular Target.Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation.Delineating the Role of Helical Intermediates in Natively Unfolded Polypeptide Amyloid Assembly and Cytotoxicity.Therapeutic Versatility of Resveratrol Derivatives.Hydrolysis and Dissolution of Amyloids by Catabodies.

P2860

Q26764754-FCA042D7-5073-49C6-96D6-8704EE0C2196 Q27671971-647102FE-4355-4E1F-BE10-D9AC8AD94E1B Q27678369-59BC6605-AF45-40E1-8D58-6E35F9363A60 Q27679360-52C50833-E1F1-4547-95CD-EB7E0A8B6B14 Q34305005-1AE81401-9698-44B9-A8C7-75B5129999F1 Q34414650-B8B07A98-9789-40C5-899D-45D6A1369311 Q34487487-A2029F0E-62AB-456B-93C7-E61E3C9E4EB3 Q34838524-08D2925D-F71A-434E-A2DD-7AD67B579190 Q34951860-E857CBF3-3B66-48A4-9191-0B9A83A07BA8 Q35783283-EC944F7A-004A-417B-AC48-87BA4007D9DE Q35901035-DCDFA95D-A1DE-4B52-B1C0-68675DD62A56 Q36035377-1E1ADF3D-A108-4A32-BB65-AE88A6583612 Q36408438-90A05F9D-53AD-444E-8561-3E2F92471C71 Q36538570-E2EC3CAE-C035-4D15-BAB6-C64D5E797A06 Q36615637-E2591FC6-B7AD-4FBC-85F3-7E23DCE22FCB Q36704037-4D30252A-3C45-42B8-AD3B-A33A13ADA234 Q37370545-9383FFD9-302B-4EFA-971E-046EB761A58F Q37975816-905BE35E-79C0-4E7F-B047-629BDA946A1F Q38517905-49574A28-B12B-4641-9D8C-87191CF2781B Q38547033-DE71DB96-AAF7-4417-864C-BF8346338F94 Q38614967-5696695D-1B7C-42E9-A01F-BD6C152294CF Q38635739-25320FB9-A6A4-40AD-A967-6B5018443E36 Q38851025-0F7DD0F0-C436-4EBC-AF1A-E63A10D8BE93 Q38951781-82AA07FA-3131-4253-A1EE-ACF6711D5DE3 Q39126169-51609A89-928A-4C73-B0C7-74BDD860582D Q39176222-0B223361-D65C-4F1B-BC2F-2BBDB7E88A9A Q39383463-1695C33C-0D07-466D-8D2C-132AD7F06689 Q42613719-BA4978AC-959E-40BF-891C-52D76FA71FA8 Q46658975-14D21E3B-6EF9-4AC2-8C80-B93EC39856F2 Q47126437-082DA750-8AAB-4D9E-BECA-7C325CD34039 Q48216989-D8422779-0AEB-434B-A88F-FA9E82ECF00D

P2860

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

http://www.wikidata.org/entity/Q35133371

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

@ast

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

@en

type

label

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

@ast

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

@en

prefLabel

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

@ast

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

@en

P1433

Q35133371-84EE865C-80A6-4118-870D-2D10A292AD07

P1476

Q35133371-739852D1-9217-4558-8428-8E10E9605900

P2093

Q35133371-07DB34E7-4AD1-44EF-9FBC-1CC3BDBC447A

Q35133371-29D1F970-F24C-44AF-B548-134F4AAA5AD6

Q35133371-55E0CB2D-FC2C-488E-92DF-FA1CB29C9984

Q35133371-8CE3A409-5C49-4264-8497-9E107F9847B7

P2860

Q35133371-0286CAB5-4C81-46F1-A711-0AB2C94DA9B6

Q35133371-1E026374-1E19-4671-B6AF-03111751E26A

Q35133371-2245FB57-946F-4606-B7FB-C24CEDE7A339

Q35133371-307DF21D-2933-4BDE-ABB7-D8D4E9082541

Q35133371-3A2320DD-F248-4767-B1C7-06FFEBFB4984

Q35133371-3AC63D17-6BF2-458D-870E-D152723F8269

Q35133371-3DA53EA5-72EA-4DB5-9560-34EE198006C1

Q35133371-40CB26D9-7A96-434D-A7EE-10CA935343F7

Q35133371-4563A11C-DACA-4571-B49B-66B46EE0131E

Q35133371-4E9F7C36-8E21-4A15-B671-D44E08DA6F0A

P304

Q35133371-D3411C23-F0FB-4062-9A39-935A8C8C806D

P31

Q35133371-27CD3BE2-0D53-4171-A378-1E2D07BE1B6E

P356

Q35133371-4F26044E-79E7-4B7F-80A0-E9C0E927F3E1

P407

Q35133371-C56619BB-513F-405C-B1EF-0CDF964CD01C

P433

Q35133371-D273F2C5-C60E-4A76-BA76-90A12A94796A

P478

Q35133371-FC3FFA7D-26B5-4B36-87B0-04A269EA02F4

P50

Q35133371-AEEB4BA2-6A92-4769-B350-AE0710629091

Q35133371-E01730FF-1529-4B9B-BEB3-B4CAC6F5A1D2

P577

Q35133371-115D6DF6-5D9F-45E2-8CD1-F0E9D3D59788

P5875

Q35133371-6460E439-97D7-4926-B70B-2A23558730D2

P698

Q35133371-AD2C8ED8-1D17-427D-AD96-42B82D72E2B9

P932

Q35133371-77BD7B19-FC4B-4423-AA51-4F611EE116D7

P356

J.BBRC.2011.04.133

P1433

Biochemical and Biophysical Research Communications

P1476

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

@en

P2093

Joshua L Price

http://www.w3.org/2001/XMLSchema#string

Natàlia Reixach

http://www.w3.org/2001/XMLSchema#string

Steve Bourgault

http://www.w3.org/2001/XMLSchema#string

Sungwook Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture

Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates

Rational design of potent human transthyretin amyloid disease inhibitors

An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured

Toward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †

A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and Cytotoxicity

Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma

A primer of amyloid nomenclature

Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro.

Trans-suppression of misfolding in an amyloid disease.

P304

707-713

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBRC.2011.04.133

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

410

http://www.w3.org/2001/XMLSchema#string

P50

Jeffery W. Kelly

P577

2011-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51113039

http://www.w3.org/2001/XMLSchema#string

P698

21557933

http://www.w3.org/2001/XMLSchema#string

P932

3145458

http://www.w3.org/2001/XMLSchema#string